Centuple Global share price
BSE: 531099Pharmaceuticals & BiotechnologySmall Cap
CENTUPLE GLOBAL LIMITED · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Sep 1995
Last close ₹35.99down ₹1.24 (3.33%)
Share price at the BSE close on 29 Oct 2026. Previous close ₹37.23.
29 Oct: open ₹36.97, high ₹36.97, low ₹35.70
52-week range of traded prices to 29 Oct 2026
₹28.42Low, 21 Sep 2026₹144.40High, 7 Jan 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹20 Cr3,666th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.94
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.53
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 94.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 22.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 3.26
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,880
Results
Standalone; ₹ crore.Centuple Global quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4,540.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +1,281.3%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.00 Crdown 100.00%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹0.18 CrQuarter to Mar 2026: −₹0.48 Cr
Revenue by quarter
Peak revenue ₹279 Cr, quarter to Mar 2026; lowest ₹0.00 Cr, quarter to Jun 2026
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 4 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 12 | 109 | 174 | 279 | 0 |
| Net profit | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | −89.6% | −17.6% | 25.2% | 0.8% | 1.2% | 0.3% | −0.2% | – |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹574 Crup 1,14,661.84%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1.51 Crup 5,834.25%
- Net margin
- 0.3%
Revenue by year
Peak revenue ₹574 Cr, year to Mar 2026; lowest ₹0.31 Cr, year to Mar 2017
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 574 |
| Net profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Net margin | 11.0% | −7.1% | −1.9% | 3.2% | 1.2% | −1.8% | −6.8% | 2.7% | 5.1% | 0.3% |
Standalone. Years to March. The latest is shaded.
Business segments
Share of revenue, year to Mar 2026, standalone.Segment revenue and profit
- FMCG ProductsFMCG Products, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹497 Cr86.7%
- Tobacco ProductsTobacco Products, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹76 Cr13.3%
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.Centuple Global PE ratio and valuation
Price to earnings
At or below today's level on 24% of 565 trading days over the last 3 years.
LowestHighest
Its median34.84Industry median28.38
Price to book
At or below today's level on 33% of 711 trading days over the last 3 years.
LowestHighest
Its median13.05Industry median2.97
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +267.4% | +5,834.3% | −93.8% | 0.0% |
| 5 years | – | +205.1% | −40.7% | – |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Return and dividend yield are left empty where a year's dividend yield in the window cannot be measured: a dividend with no amount stated, or no price at the year end. Earnings growth over 1 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Centuple Global competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Centuple Global in market cap. 1 company in the table last traded before then: its row is priced on its last trade.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Lasa SupergenericsLASA | 23 | – | 0.47 | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 22 | 31.24 | 1.91 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
 Zenith Health CareZENITHHE | 21 | 498.91 | 2.76 | −5.4% | – | 0.6% | −4.1% | 0.00% |
 Colinz LaboratoriesCOLINZ | 18 | 6.34 | 1.39 | +1.7% | +500.5% | 24.6% | 1.5% | 0.00% |
 Span DivergentSDL | 17 | – | 1.17 | +171.7% | – | – | −24.0% | 0.00% |
 Star Source Multi TradeSTARSOURCE | 17 | – | 12.91 | – | – | −0.5% | −3.1% | 0.00% |
| Mono PharmacareMONOPHARMA | 16 | 44.15 | 0.50 | −1.6% | −88.3% | 1.1% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Centuple Global announcements
Oct 2026
13 Oct · Meeting
12 Oct · Board meeting
8 Oct · Board meeting
Meeting on 12 Oct 20261 Oct · Meeting
1 Oct · Meeting
Centuple Global share price by year
Each calendar year to 2025.Centuple Global share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 114.26 | +775.6% | 114.26 | 9.55 |
| 2024 | 13.05 | +181.3% | 17.13 | 4.87 |
| 2023 | 4.64 | +3.1% | 5.46 | 3.95 |
| 2022 | 4.50 | +11.1% | 4.52 | 2.72 |
| 2021 | 4.05 | +71.6% | 4.26 | 1.79 |
| 2020 | 2.36 | −17.8% | 2.87 | 1.24 |
| 2019 | 2.87 | +58.6% | 4.19 | 1.72 |
| 2018 | 1.81 | −65.8% | 6.00 | 1.81 |
| 2017 | 5.30 | +265.5% | 6.01 | 1.37 |
| 2015 | 1.45 | −62.8% | 4.37 | 1.45 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2023 is from its first session, 13 Feb 2023. 2022 is from its first session, 17 Jan 2022. 2017 is from its first session, 23 Feb 2017. The change in 2017 is on the close at the end of 2015, the last year before it with a trade. The close is the year's last trade for 2019 (18 Dec 2019) and 2015 (25 Aug 2015).
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 28 Oct 2026 | 37.50 | 37.50 | 35.25 | 37.23 | 35.88 | 3,120 |
| 27 Oct 2026 | 38.85 | 38.85 | 37.04 | 37.08 | 38.10 | 2,154 |
| 26 Oct 2026 | 37.00 | 38.85 | 35.24 | 38.85 | 36.33 | 4,253 |
| 23 Oct 2026 | 35.90 | 37.25 | 35.33 | 37.06 | 35.81 | 2,456 |
| 22 Oct 2026 | 33.34 | 36.77 | 33.34 | 35.86 | 35.73 | 673 |
| 21 Oct 2026 | 35.09 | 35.10 | 34.90 | 35.02 | 35.00 | 3,046 |
| 19 Oct 2026 | 32.71 | 34.10 | 31.13 | 33.51 | 32.71 | 1,189 |
| 16 Oct 2026 | 32.71 | 32.71 | 32.71 | 32.71 | 32.71 | 13 |
| 15 Oct 2026 | 32.24 | 32.24 | 32.09 | 32.23 | 32.22 | 1,676 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 531099
- ISIN
- INE396H01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.rubramed.com
- CIN
- L46307MH1991PLC326598
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1991
- Registered office
- 604, 6th Floor, at Meghdoot, Mogul Lines Staff CHSL, Gulmohar Cross Road No. 6, JVPD Scheme, Mumbai 400049, Maharashtra
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments